Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelial Cells | 6 | 2019 | 527 | 1.010 |
Why?
|
| Nitric Oxide Synthase Type III | 7 | 2019 | 220 | 0.830 |
Why?
|
| Ritonavir | 3 | 2019 | 54 | 0.810 |
Why?
|
| Ginsenosides | 1 | 2019 | 21 | 0.630 |
Why?
|
| Superoxide Dismutase | 2 | 2019 | 139 | 0.630 |
Why?
|
| Estrogen Receptor beta | 1 | 2019 | 79 | 0.610 |
Why?
|
| Endothelium, Vascular | 5 | 2011 | 514 | 0.550 |
Why?
|
| Vasodilation | 3 | 2011 | 191 | 0.410 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2010 | 23 | 0.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 667 | 0.280 |
Why?
|
| Down-Regulation | 4 | 2019 | 697 | 0.240 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 32 | 0.230 |
Why?
|
| Oxidative Stress | 6 | 2019 | 795 | 0.230 |
Why?
|
| Splanchnic Circulation | 1 | 2024 | 52 | 0.220 |
Why?
|
| Neoplasms | 3 | 2024 | 2758 | 0.210 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 145 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2024 | 180 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 161 | 0.190 |
Why?
|
| Masoprocol | 2 | 2011 | 10 | 0.190 |
Why?
|
| Coronary Vessels | 3 | 2010 | 526 | 0.180 |
Why?
|
| Antioxidants | 3 | 2011 | 338 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2024 | 581 | 0.160 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2113 | 0.160 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 87 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 481 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1438 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2019 | 863 | 0.130 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 477 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 106 | 0.120 |
Why?
|
| Mutation | 2 | 2024 | 5775 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 98 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2015 | 242 | 0.120 |
Why?
|
| Swine | 4 | 2011 | 1155 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 240 | 0.110 |
Why?
|
| Cell Line | 1 | 2019 | 2772 | 0.110 |
Why?
|
| Hair Follicle | 1 | 2013 | 34 | 0.110 |
Why?
|
| Twist-Related Protein 1 | 1 | 2013 | 36 | 0.110 |
Why?
|
| Health | 1 | 2013 | 37 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 413 | 0.110 |
Why?
|
| Larrea | 1 | 2011 | 5 | 0.100 |
Why?
|
| Benzyl Alcohols | 1 | 2011 | 14 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1682 | 0.100 |
Why?
|
| HIV Protease Inhibitors | 1 | 2011 | 53 | 0.100 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 203 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 89 | 0.090 |
Why?
|
| Resistin | 1 | 2010 | 36 | 0.090 |
Why?
|
| Bradykinin | 1 | 2010 | 57 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2010 | 3042 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 133 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 1386 | 0.080 |
Why?
|
| Superoxides | 4 | 2011 | 154 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2010 | 2813 | 0.080 |
Why?
|
| Ghrelin | 1 | 2008 | 51 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2010 | 163 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2008 | 104 | 0.080 |
Why?
|
| Homocysteine | 1 | 2008 | 121 | 0.080 |
Why?
|
| CD40 Ligand | 1 | 2008 | 64 | 0.080 |
Why?
|
| RNA Interference | 1 | 2010 | 496 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 439 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 1265 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 1174 | 0.070 |
Why?
|
| Humans | 12 | 2024 | 123232 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2024 | 3316 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 12 | 0.060 |
Why?
|
| Animals | 8 | 2015 | 33765 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 101 | 0.060 |
Why?
|
| Disease Progression | 2 | 2024 | 2025 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2478 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 269 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2024 | 459 | 0.040 |
Why?
|
| Risk Factors | 2 | 2024 | 10015 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1687 | 0.040 |
Why?
|
| HIV Infections | 1 | 2011 | 1874 | 0.040 |
Why?
|
| Time Factors | 2 | 2024 | 6221 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 2406 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1232 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2015 | 3718 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 2010 | 439 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 19098 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 3048 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2015 | 64 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2010 | 1608 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3560 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 93 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 4514 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 239 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2015 | 237 | 0.030 |
Why?
|
| Middle Aged | 2 | 2024 | 26017 | 0.030 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2015 | 137 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 244 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 29072 | 0.030 |
Why?
|
| Female | 4 | 2024 | 65551 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 652 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2013 | 423 | 0.030 |
Why?
|
| Morphogenesis | 1 | 2013 | 210 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2011 | 106 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1339 | 0.020 |
Why?
|
| Male | 3 | 2024 | 60122 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 49 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2011 | 122 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 163 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2010 | 51 | 0.020 |
Why?
|
| Catalase | 1 | 2010 | 50 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1695 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 193 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 91 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 966 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 482 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 130 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 512 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 287 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 256 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2010 | 347 | 0.020 |
Why?
|
| Anions | 1 | 2008 | 18 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 69 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 3274 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2010 | 176 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1872 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2008 | 137 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 248 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 17509 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2010 | 280 | 0.020 |
Why?
|
| DNA Damage | 1 | 2010 | 505 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 315 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 372 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 523 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 16033 | 0.020 |
Why?
|
| Oxygen | 1 | 2008 | 547 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1443 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2010 | 831 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4490 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1863 | 0.010 |
Why?
|